9-(3-Dimethylamino-propyliden)-thioxanthen | 24145-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 英文名称: 9-(3-Dimethylamino-propyliden)-thioxanthen
• 英文别名: Prothixene；N,N-dimethyl-3-thioxanthen-9-ylidenepropan-1-amine
• CAS: 24145-25-3
• 化学式: C₁₈H₁₉NS
• 分子量: 281.422
• InChiKey: JJSMYTSEKDSFKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  9-(3-dimethylamino-propyl)-thioxanthen-9-ol 在 硫酸 作用下， 生成 9-(3-Dimethylamino-propyliden)-thioxanthen
  参考文献：
  名称：

  Jilek et al., Cesko-Slovenska Farmacie, 1965, vol. 14, p. 294,296

  摘要：

  DOI：

文献信息

• [EN] Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy<br/>[FR] DÉRIVÉS D'AMINOTÉTRALINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR UTILISATION EN THÉRAPIE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2010092180A1

  公开（公告）日：2010-08-19

  The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GIyT1 inhibitors.

  本发明涉及式(I)的氨基四氢喹啉衍生物或其生理可容忍的盐。该发明涉及包含这样的氨基四氢喹啉衍生物的药物组合物，以及将这样的氨基四氢喹啉衍生物用于治疗目的。所述氨基四氢喹啉衍生物是GIyT1抑制剂。
• [EN] BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY<br/>[FR] DÉRIVÉS DE BENZAZÉPINE, COMPOSITIONS PHARMACEUTIQUES CONTENANT CEUX-CI, ET LEUR UTILISATION EN THÉRAPIE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2012152915A1

  公开（公告）日：2012-11-15

  The present invention relates to benzazepine derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such benzazepine derivatives, and the use of such benzazepine derivatives for therapeutic purposes.

  本发明涉及式(I)的苯并氮杂环衍生物或其生理耐受盐。本发明还涉及包含这种苯并氮杂环衍生物的药物组合物，以及利用这种苯并氮杂环衍生物进行治疗目的的用途。
• [EN] HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS INHIBITORS OF THE GLYCINE TRANSPORTER 1<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR UTILISATION COMME INHIBITEURS DU TRANSPORTEUR 1 DE LA GLYCINE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2010092181A1

  公开（公告）日：2010-08-19

  The present invention relates to heterocyclic compounds of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such heterocyclic compounds, and the use of such heterocyclic compounds for the manufacture of a medicament for inhibiting the glycine transporter GIyT1.

  本发明涉及公式（I）的杂环化合物或其生理耐受盐。本发明还涉及包含这种杂环化合物的药物组合物，以及利用这种杂环化合物制造用于抑制甘氨酸转运蛋白GIyT1的药物的用途。
• [EN] PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY<br/>[FR] DÉRIVÉS DE PHÉNALKYLAMINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION EN THÉRAPIE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2012020130A1

  公开（公告）日：2012-02-16

  The present invention relates to phenalkylamine derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of such phenalkylamine derivatives for therapeutic purposes. The phenalkylamine derivatives are GlyT1 inhibitors.

  本发明涉及式(I)的苯丙胺衍生物或其生理耐受盐。本发明涉及包含这种苯丙胺衍生物的药物组合物，以及利用这种苯丙胺衍生物进行治疗的用途。这些苯丙胺衍生物是GlyT1抑制剂。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。